AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Favorable OvaRex Phase II Trial Results Reported.
2001 JAN 25 - (NewsRx.com) -- AltaRex Corp. (AXO, ALRXF), Waltham, Massachusetts, reported the final results of one of its OvaRex Phase II trials conducted by Thomas Ehlen, MD, FRCSC, at the Vancouver Cancer Center in British Columbia, Canada.
The company also announced preliminary results of a second OvaRex Phase II trial conducted by Alan Gordon, MD, U.S. Oncology in Houston, Texas. Both trials address patients with very advanced recurrent ovarian cancer where the future prognosis is extraordinarily poor.
In the Vancouver study, six of 13 OvaRex-treated patients survived 50 weeks or longer without any significant OvaRex-associated toxicity, even though they had very advanced disease and had exhausted all treatment alternatives. One of the six patients survived over two years and two of the six patients are still alive almost two years later.
By comparison, approved "salvage" chemotherapies (Doxil, Hycamptin) for this population are generally expected to provide a survival benefit of approximately one year, but in contrast to OvaRex monoclonal antibody (MAb), are associated with significant toxicities.
In the Dallas study, patients receive OvaRex MAb followed by "salvage" chemotherapy and then a final dose of OvaRex MAb. This population is at a somewhat earlier stage of disease than the Vancouver trial, thereby allowing for this study design. ...
- OvaRex phase III clinical trial initiated.
- Newspaper article from: Pharma Business Week February 17, 2003 700+ words
...months with results by mid-2005. OvaRex MAb has been granted Orphan Drug status...plans for European registration of OvaRex MAb that would center on the Unither...Cancer (EORTC) on a possible OvaRex phase II trial conducted by AltaRex and...
- OvaRex Phase III Trials Are Fully Enrolled.
- Press release article from: PR Newswire June 20, 2006 700+ words
...achieved in a Phase II front-line trial of OvaRex in combination with chemotherapy, with a total of 40 patients enrolled. OvaRex MAb-B43.13 (oregovomab) is an investigational immunotherapeutic monoclonal antibody being developed for the treatment of...
- OvaRex Phase III trials are fully enrolled.
- News wire article from: Chemical Business Newsbase June 20, 2006 700+ words
...achieved in a Phase II front-line trial of OvaRex in combination with chemotherapy, with a total of 40 patients enrolled. OvaRex MAb-B43.13 (oregovomab) is an investigational immunotherapeutic monoclonal antibody being developed for the treatment of...
- OvaRex MAb for Patients with Advanced Ovarian Cancer May Extend Remission...
- Press release article from: Business Wire February 10, 2005 700+ words
...Results of the most recently completed OvaRex MAb clinical study were published in the...treatment" group, patients who received OvaRex MAb experienced a longer period of remission...treatment. "We've learned so much about OvaRex MAb but we now need to confirm these observations...
- ViRexx announces enrolment completion of Ovarex MAb Phase III trial for ovarian...
- News wire article from: Chemical Business Newsbase December 14, 2005 700+ words
...of two identical Phase III trials for OvaRex MAb, Impact I and Impact II. The Impact...completed front-line therapy. The OvaRex MAb trials are being conducted and funded...trial is 177 patients, randomised 2:1 OvaRex MAb versus placebo. The primary endpoint...
- ViRexx announces completion of enrollment for Phase III OvaRex MAb trials.
- News wire article from: Chemical Business Newsbase June 22, 2006 700+ words
...s (Unither), Phase III trials for OvaRex MAb for patients with stage III/IV advanced...trial is time-to-relapse comparing OvaRex MAb and placebo with the primary data analysis...controlled trials, randomised 2:1 OvaRex MAb versus placebo, are being conducted...
- PRESS RELEASE: AltaRex to present OvaRex MAb in Europe at ECCO 11 meeting.
- News wire article from: Chemical Business Newsbase October 31, 2001 700+ words
AltaRex Corp announced that OvaRex MAb, the company's lead product in late...and the patient's own tumour) when OvaRex MAb was administered after surgery and then...findings from this study demonstrate that OvaRex MAb did not diminish the effect of salvage...
- Press Release: AltaRex achieves major manufacturing milestone for OvaRex Mab.
- News wire article from: Chemical Business Newsbase January 9, 2002 700+ words
...to file an amendment to its Investigational New Drug submission for OvaRex MAb with the US Food and Drug Administration (FDA) and to commence the...company's Biologics License Application for regulatory approval of OvaRex MAb.
- Dompe International SA, of Lausanne, Switzerland, and AltaRex Medical Corp., of...
- Newspaper article from: BioWorld International July 14, 2004 700+ words
...and AltaRex Medical Corp., of Edmonton, Alberta, signed an exclusive distribution agreement for AltaRex's lead product OvaRex MAb. The covered territory includes Italy, Spain, Portugal, Hungary, Poland, Czech Republic, Switzerland and Austria...
- OvaRex MAb Selected as one of 100 Great Investigational Drugs.
- Press release article from: Business Wire May 18, 2004 700+ words
Business Editors EDMONTON, AlbertaBUSINESS WIREMay 18, 2004 AltaRex Medical Corp. (TSX: ALT) ("AltaRex" or the "Company") is pleased to announce that the Company's lead product candidate, OvaRex(R) MAb, has been selected by R&D Directions magazine as one of 100 Great Investigational Drugs. The
Source: HighBeam Research, Favorable OvaRex Phase II Trial Results Reported.